Clinical trials: Conjunctivitis, Allergic
Persistent Corneal Epithelial Defect
An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED
This is a phase 3, randomized, multicenter, double-masked, parallel group, vehicle-controlled prospective clinical trial to evaluate the safety and efficacy of cenegermin in inducing complete epithelial healing in participants…
- Trial name
- NCT07519902
- Testing
- Cenegermin, Vehicle
- Where
- 77 sites in United States, Argentina and 12 more
- Volunteers
- 150 people
- Sponsor
- Dompé Farmaceutici S.p.A
Allergic Conjunctivitis of Both Eyes
Daydrop® Triple Action for Allergic Eye Symptoms
The study is designed to evaluate the safety and efficacy of Daydrop® Triple Action for the symptomatic treatment of seasonal or perennial allergic conjunctivitis.
- Trial name
- NCT07805759
- Testing
- Eye Drops, Lubricant
- Where
- Spain
- Volunteers
- 49 people
- Sponsor
- i+Med S.Coop.
Allergic Conjunctivitis
Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy
This study is researching 2 experimental drugs, REGN5713 and REGN5715. The study drugs will be either of these drugs given alone (either REGN5713 or REGN5715) or given together (REGN5713 and REGN5715) to reduce eye allergy signs…
- Trial name
- NCT07309432
- Testing
- REGN5713, REGN5715
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Regeneron Pharmaceuticals
Allergic Conjunctivitis
A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy
This study is researching two experimental medicines, freneslerbart and mevonlerbart. Freneslerbart and mevonlerbart can be given alone or together. When given together, the medicine is called "REGN-2Cat".
- Trial name
- NCT07675811
- Testing
- REGN-2Cat, Freneslerbart, Mevonlerbart
- Where
- United States
- Volunteers
- 570 people
- Sponsor
- Regeneron Pharmaceuticals
Conjunctivitis Allergic
A Study to Identify and Characterize Adults and Pediatric Participants With Cat and/or Birch Allergy
The purpose of this Patient Identification and Characterization (PIC) study is to collect information and perform limited allergy-related procedures to determine if participants can qualify for cat and/or birch tree pollen…
- Trial name
- NCT07710846
- Testing
- Noninterventional
- Volunteers
- 1,500 people
- Sponsor
- Regeneron Pharmaceuticals
Allergic Conjunctivitis
The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis
The INVIGORATE 2 Trial: A single-center, randomized, double-masked, crossover design, vehicle-controlled, Phase 3 clinical trial to assess the efficacy and safety of reproxalap ophthalmic solution (0.25%) compared to vehicle in…
- Trial name
- NCT05234554
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
- Where
- Canada
- Volunteers
- 131 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Allergic Conjunctivitis
A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy
This study is researching 2 experimental drugs, REGN1908 and REGN1909, which are called REGN1908-1909 when mixed together (called "study drug") to reduce eye allergy signs and symptoms from cat allergy.
- Trial name
- NCT06602726
- Testing
- REGN1908, REGN1909
- Where
- 4 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- Regeneron Pharmaceuticals
Moderate to Severe Vernal Keratoconjunctivitis
A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis
The aim of the study is to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants with Moderate to Severe Vernal Keratoconjunctivitis
- Trial name
- NCT07169695
- Testing
- Slit Lamp Examination, Far Best Corrected Visual Acuity (BCVA), T1695
- Where
- 11 sites in India
- Volunteers
- 120 people
- Sponsor
- Laboratoires Thea
Allergic Conjunctivitis
A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy
This study is researching 2 experimental drugs, REGN5713 and REGN5715, which are called REGN5713-5715 when mixed together (called "study drug") to reduce eye allergy signs and symptoms due to birch tree pollen allergy.
- Trial name
- NCT06602739
- Testing
- REGN5713, REGN5715
- Where
- 3 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Regeneron Pharmaceuticals
Allergic Rhinitis, Allergic Conjunctivitis
The Effects of Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops Compared to Placebo
The primary objective of this study is to assess the relative efficacy of Ectoin® Allergy Eye Drops and Ectoine® Allergy Nasal Spray compared to placebo, by evaluating Total Nasal Symptom Score (TNSS) and Total Ocular Symptom…
- Trial name
- PPL-003 (NCT01471184)
- Testing
- Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops
- Where
- Canada
- Volunteers
- 46 people
- Sponsor
- Bitop AG
Allergic Rhinitis Due to Pollen, Allergic Conjunctivitis
Tyrosine Allergoid Paediatric and Adult Study
The primary objective of this 5-year study is to demonstrate non-inferiority of children compared to adults by exploring long-term effectiveness after treatment with TA Bäume (trees) and TA Gräser (grass) following a perennial…
- Conditions
- Allergic Rhinitis Due to Pollen, Allergic Conjunctivitis, Allergic Asthma
- Trial name
- NCT05186025
- Testing
- MATA trees or MATA grass
- Where
- Germany
- Volunteers
- 320 people
- Sponsor
- Allergy Therapeutics
Allergic Conjunctivitis
Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis
In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 60 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered…
- Trial name
- NCT07220408
- Testing
- TL-925
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Telios Pharma, Inc.
Allergic Conjunctivitis
Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies
The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of allergic conjunctivitis using an antigen challenge model
- Trial name
- NCT04622345
- Testing
- VSJ-110
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Vanda Pharmaceuticals
Allergic Rhinitis Due to House Dust Mite, Allergic Conjunctivitis Due to Dermatophagoides Farinae
Noninterventional Study on Tolerability and Safety of One Strength Updosing With Novo-Helisen Depot House Dust Mites
The goal of this non-interventional study is to investigate the safety and tolerability of a new simplified up-dosing schedule for Novo-Helisen Depot.
- Conditions
- Allergic Rhinitis Due to House Dust Mite, Allergic Conjunctivitis Due to Dermatophagoides Farinae, Allergic Conjunctivitis Due to Dermatophagoides Pteronyssinus, Allergic Asthma Due to Dermatophagoides Farinae
- Trial name
- NOVUS-UP (NCT07096440)
- Volunteers
- 105 people
- Sponsor
- Allergopharma GmbH & Co. KG
Allergic Conjunctivitis
Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution
To compare the safety and tolerability of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% combination ophthalmic solution versus its vehicle in healthy adult subjects and in pediatric subjects.
- Trial name
- NCT05815758
- Testing
- Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo), Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution
- Where
- 7 sites in United States
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Seasonal Allergic Conjunctivitis
Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis
To evaluate the efficacy of Combo compared to its individual components and compared to vehicle in a population of subjects with seasonal allergic conjunctivitis.
- Trial name
- NCT05591755
- Testing
- Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution, Ketotifen fumarate ophthalmic solution 0.035%, Brimonidine tartrate ophthalmic solution 0.025%
- Where
- 6 sites in United States
- Volunteers
- 229 people
- Sponsor
- Bausch & Lomb Incorporated
Allergic Rhino-Conjunctivitis, Urticaria
To Compare and Evaluate the Oral Bioavailability of Bilastine 20 mg Orally Dispersible Tablet With That of Bilaxten (Bilastine) 20 mg Orally Dispersible Tablet in Healthy, Adult, Human Subjects Under Fasting Conditions
An open label, balanced, randomized single-dose, two-treatment, two sequence, four-period, Full Replicate, crossover oral bioequivalence study in healthy, adult, human subjects under fasting condition.
- Trial name
- NCT07042828
- Testing
- Bilastine oral dispersible tablets, Bilaxten oral dispersible tablets
- Where
- India
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Keratoconjunctivitis, Atopic, Keratoconjunctivitis, Vernal
Topical rVA576 for Treatment of Atopic Keratoconjunctivitis
Topical rVA576 for treatment of atopic keratoconjunctivitis (AKC), vernal keratoconjunctivitis (VKC),and severe allergic conjunctivitis (seasonal (SAC) or perennial (PAC)): a randomised placebo-controlled double masked parallel…
- Conditions
- Keratoconjunctivitis, Atopic, Keratoconjunctivitis, Vernal, Conjunctivitis, Allergic
- Trial name
- NCT04037891
- Testing
- rVA576
- Where
- 9 sites in Spain, United Kingdom
- Volunteers
- 12 people
- Sponsor
- AKARI Therapeutics
Allergic Conjunctivitis
A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis
A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Methodology Development Environmental Clinical Trial with Reproxalap Ophthalmic Solutions (0.25% and 0.5%) in Subjects with Seasonal Allergic…
- Trial name
- NCT03660878
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Conjunctivitis, Allergic
A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber
An Exploratory Clinical Trial Evaluating Reproxalap Ophthalmic Solutions (0.25% and 0.5%) in Subjects with Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber (EEC)
- Trial name
- NCT03709121
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Aldeyra Therapeutics, Inc.